KinoTeck Therapeutics Co., Ltd

Location not on file

OncologyPhase II

Compare Sign in to watch

What changed

Study registered, no phase assigned: AI Multimodal Model for Liver Cancer Diagnosis and Prognosis

2w agoTrial registeredJul 1, 2026Source filing (opens the source filing in a new tab)

Momentum

84no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,147 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
Study registered
Dec 1, 2025
Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma (Icc) · ACTIVE_NOT_RECRUITING · sponsor: Guangxi Medical University · AI Multimodal Model for Liver Cancer Diagnosis and Prognosis
ClinicalTrials.gov · NCT07658586 (opens the source filing in a new tab)
Grant
K99 · $123k · non-dilutive
Jun 16, 2025
HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI WANG, FENGLEI · NIA · award ends Jan 17, 2026 · Molecular profiles for mortality risk and longevity: a multiomics approach
NIH RePORTER · NIH RePORTER 11052041 (opens the source filing in a new tab)
Grant
R35 · $484k · non-dilutive
May 22, 2025
UT SOUTHWESTERN MEDICAL CENTER · PI WANG, FEI · NIGMS · award ends Mar 31, 2030 · Determining the roles of autophagy in gametogenesis in S. cerevisiae
NIH RePORTER · NIH RePORTER 11011416 (opens the source filing in a new tab)
Trial
PHASE1 registered
Mar 31, 2025
Solid Tumors with FGFR2 Alterations, Adult · NOT_YET_RECRUITING · sponsor: KinoTeck Therapeutics Co., Ltd · A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations
ClinicalTrials.gov · NCT06800196 (opens the source filing in a new tab)
Grant
R01 · $559k · non-dilutive
Aug 1, 2024
MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WANG, FAN · NIDCD · award ends May 31, 2029 · The brainstem vocal control circuits
NIH RePORTER · NIH RePORTER 11140506 (opens the source filing in a new tab)
Grant
U24 · $614k · non-dilutive
May 1, 2023
MASSACHUSETTS GENERAL HOSPITAL · PI WANG, FUYIXUE · NINDS · award ends Apr 30, 2028 · Advancing fMRI Acquisition through Dissemination of EPTI- An Efficient Distortion-Free Multi-Contrast Imaging Technology
NIH RePORTER · NIH RePORTER 11082433 (opens the source filing in a new tab)
Grant
P20 · $450k · non-dilutive
Apr 6, 2023
BOISE STATE UNIVERSITY · PI DAVIS, PAUL HENRY · NIGMS · award ends Jan 31, 2028 · FABRICATION, CHARACTERIZATION, AND TESTING CORE (FaCT CORE)
NIH RePORTER · NIH RePORTER 11064801 (opens the source filing in a new tab)
Grant
K00 · $99k · non-dilutive
Aug 1, 2022
DANA-FARBER CANCER INST · PI WANG, FANGYU · NCI · award ends May 31, 2028 · SIRT1 Regulates RNA Stability to Promote Breast Cancer
NIH RePORTER · NIH RePORTER 11094157 (opens the source filing in a new tab)
Grant
R01 · $773k · non-dilutive
May 1, 2022
CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · NIA · award ends Apr 30, 2027 · Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatments
NIH RePORTER · NIH RePORTER 11212181 (opens the source filing in a new tab)
Grant
R35 · $863k · non-dilutive
May 1, 2022
UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JIN, YISHI · NINDS · award ends Apr 30, 2030 · Molecular genetics of axon and synapse development and maintenance
NIH RePORTER · NIH RePORTER 11067778 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jan 15, 2019
Solid Tumor, Advanced Cancer · RECRUITING · sponsor: Sun Yat-sen University · Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
ClinicalTrials.gov · NCT03810339 (opens the source filing in a new tab)
Grant
R01 · $96k · non-dilutive
Mar 3, 2017
UNIVERSITY OF KENTUCKY · PI XU, REN · NCI · award ends Oct 17, 2025 · Roles of Hsp47 in Breast Cancer Progression
NIH RePORTER · NIH RePORTER 11088251 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the trial record at 0.36same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Study registered, no phase assigned: AI Multimodal Model for Liver Cancer Diagnosis and Prognosis
2w agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
2mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH K99 · $0.1M · Molecular profiles for mortality risk and longevity: a multiomics approach
Jun 2025New grantSource (opens the source filing in a new tab)
NIH P20 · $0.5M · FABRICATION, CHARACTERIZATION, AND TESTING CORE (FaCT CORE)
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R35 · $0.5M · Determining the roles of autophagy in gametogenesis in S. cerevisiae
May 2025New grantSource (opens the source filing in a new tab)
NIH U24 · $0.6M · Advancing fMRI Acquisition through Dissemination of EPTI- An Efficient Distortion-Free Multi-Contrast Imaging Technology
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · The brainstem vocal control circuits
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH K00 · $0.1M · SIRT1 Regulates RNA Stability to Promote Breast Cancer
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.1M · Roles of Hsp47 in Breast Cancer Progression
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.8M · Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatments
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R35 · $0.9M · Molecular genetics of axon and synapse development and maintenance
Apr 2025Grant renewalSource (opens the source filing in a new tab)
Phase I trial registered: A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations
Jan 2025Trial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

Study registered

K99 · $123k · non-dilutive

R35 · $484k · non-dilutive

PHASE1 registered

R01 · $559k · non-dilutive

U24 · $614k · non-dilutive

P20 · $450k · non-dilutive

K00 · $99k · non-dilutive

R01 · $773k · non-dilutive

R35 · $863k · non-dilutive

PHASE2 registered

R01 · $96k · non-dilutive